The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. (DFCI) a $766,773 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant supports the development and evaluation of a patient-facing electronic health application (app) for the PREMMPLUS risk assessment model. The PREMMPLUS model predicts an individual's risk of carrying a pathogenic variant associated with 18 hereditary cancer syndromes.
The key products and services to be delivered under this 5-year project include: 1) Conducting a multi-center implementation study to evaluate the PREMMPLUS app in diverse community health settings, 2) Assessing barriers and facilitators to systematic hereditary cancer risk assessment and refining strategies for scalability and sustainability, and 3) Building EHR-compatible applications to further increase the scalability and sustainability of hereditary cancer risk assessment. The goal is to produce a scalable and sustainable approach to hereditary cancer multigene testing that can be widely adopted in various healthcare systems.
Generated 3/4/25, 6:16 AM